Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebelimab + emacetinib ± chemotherapy in first-line advanced NSCLC
ChiCTR2500103941Phase 4Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Jul 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of adebrelimab and emacetinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Henan Cancer Hospital. Primary endpoint: Overall response rate. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
adebrelimabemacetinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500103941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500103941.